The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy

December 17, 2013
Adil Daud, MD

Special Reports, Melanoma (Issue 1), Volume 1, Issue 1

Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.

Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.

At the Society for Melanoma Research 2013 Congress, Daud presented an overall survival update for BRF113220 part C, a phase II three-arm randomized study of dabrafenib alone versus combination of dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma.

Read about the treatment of melanoma withcombinations and immunotherapies